KRAS mutational status assessment in patients with metastatic colorectal cancer: Are the clinical implications so clear?

European Journal of Cancer Care

Volumn 19, Issue 2, 2010, Pages 167-171

  Hebbar, M ^a   Fournier, P ^a   Romano, O ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cetuximab; Colorectal cancer; KRAS mutations; Panitumumab

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CETUXIMAB; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IFL PROTOCOL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; HUMAN; METASTASIS; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; SECONDARY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; GENES, MCC; HUMANS; LEUCOVORIN; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 76949095166     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01134.x     Document Type: Review

References (29)

1. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery 2004, 240:644-657.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:1626-1634.
3. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. ASCO congress. Journal of Clinical Oncology 2008, 26:4000. Suppl.), abstr
4. Bouché O, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L, Rougier P, Gargot D, Gasmi M, Ducreux M. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. ASCO congress. Journal of Clinical Oncology 2007, 25:4069. Suppl.), abstr
5. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005, 23:1803-1810.
6. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Suzuki S, Yassine M, Deeter R, Sikorski R. Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI. ASCO congress. Journal of Clinical Oncology 2008, 26:4127. Suppl.), abstr
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 2004, 1351:337-345.
8. Di Fioré F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer 2007, 96:1166-1169.
9. Di Fioré F, Van Cutsem E, Laurent-Puig P, Siena S, Frattini M, De Roock W, Lièvre A, Sartore-Bianchi A, Bardelli A, Tejpar S. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. ASCO congress. Journal of Clinical Oncology 2008, 26:4035. Suppl.), abstr
10. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C, Boige V. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology 2008, 74:17-24.
11. Duffour J, Gourgou S, Desseigne F, Debrigode C, Mineur L, Pinguet F, Poujol S, Chalbos P, Bressole F, Ychou M. Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 2007, 60:383-389.
12. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs 2006, 17:855-857.
13. Hebbar M, di Fioré F, Giraud C, Giraud C, Gasnault L, Fournier C, Péreira R, Bouché O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A. Assessment of easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Oncology 2007, 73:185-191.
14. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. The New England Journal of Medicine 2007, 357:2040-2048.
15. Karapetis C, Khambata-Ford S, Jonker D, O'Callaghan C, Tu D, Tebbutt N, Simes J, Langer C, Moore M, Zalcberg JO. KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer - results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. 2008, 10th World Congress on Gastrointestinal Cancer. Abstr 0.037
16. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
17. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Journal of Clinical Oncology 2006, 24:4914-4921.
18. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006, 66:3992-3995.
19. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology 2008, 26:374-379.
20. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clinical Cancer Research 2002, 8:994-1003.
21. Rivoire M, Thezenas S, Rebischung C, Viret F, Guimbaud R, François E, Ducreux M, Quenet F, Desseigne F, Ychou M. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP). ASCO congress. Journal of Clinical Oncology 2008, 26:4075. Suppl.), abstr
22. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370:143-152.
23. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:2311-2319.
24. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004, 22:229-237.
25. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Köhne C. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO congress. Journal of Clinical Oncology 2007, 25:4000. Suppl.), abstr
26. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. ASCO congress. Journal of Clinical Oncology 2008a, 26:2. Suppl.), abstr
27. Van Cutsem E, Lang I, D'Haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Nippgen J, Stroh C, Rougier P. KRAS status and efficacy in the CRYSTAL study: first-line treatment of patients with metastatic colorectal cancer receiving FOLFIRI with or without cetuximab. European Society of Medical Oncology Meeting. Annals of Oncology 2008b, 19(Suppl 6):710. abstr
28. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of Oncology 2002, 13:1841-1851.
29. Ychou M, Raoul JL, Desseigne F, Borel C, Caroli-Bosc FX, Jacob JH, Seitz JF, Kramar A, Hua A, Lefebvre P, Couteau C, Merrouche Y. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology 2002, 50:383-391.